Welcome to our dedicated page for WW International SEC filings (Ticker: WW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for WW International, Inc. (WeightWatchers), historically associated with the ticker WW and, during its Chapter 11 process, WGHTQ on OTC Markets. These filings offer detailed information on the company’s financial condition, capital structure, governance, and material events that shape its weight management and clinical businesses.
WeightWatchers uses periodic reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q to disclose its subscription-based business model, including Behavioral and Clinical Subscription Revenues, Other Revenues, and metrics like Incoming Subscribers, End of Period Subscribers, and Monthly Subscription Revenues Per Average Subscriber. These documents explain how the company defines its Behavioral and Clinical businesses and how management evaluates subscriber and revenue trends.
Current reports on Form 8‑K, several of which are referenced here, describe material developments such as quarterly earnings releases, leadership changes, and the company’s 2025 financial reorganization. A June 25, 2025 Form 8‑K outlines the confirmation and effectiveness of the prepackaged Chapter 11 plan of reorganization, the discharge of prepetition credit facilities and senior secured notes, the issuance of new common stock, and the cancellation of prior equity securities. Subsequent 8‑Ks furnish earnings press releases and shareholder letters for fiscal quarters following emergence.
A Form 25 filed by Nasdaq Stock Market LLC on July 3, 2025 documents the removal from listing and registration of the company’s old common stock, which was canceled in the bankruptcy proceeding. Together, these filings trace the evolution of WeightWatchers’ capital structure, listing status, and governance framework.
On Stock Titan, SEC documents for WW are supplemented with AI-powered summaries that highlight key points from long filings, helping readers understand complex topics such as fresh start accounting, new credit agreements, changes in control, and definitions of non‑GAAP metrics like Adjusted EBITDA. Users can also review insider and governance-related disclosures in Forms 3, 4, and 5 when available, alongside proxy materials that address board composition and director compensation. This combination of real-time EDGAR updates and AI explanations makes it easier to follow how regulatory disclosures relate to WeightWatchers’ behavioral and clinical weight health strategy.
WW International, Inc., known as Weight Watchers, appointed Lisa Gavales and Sue E. Gove as independent directors effective April 7, 2026. They will serve until the 2026 annual meeting and are expected to stand for election.
The Board increased to six directors, all classified as independent under Nasdaq listing standards. Each new director will receive an annual cash retainer of $90,000, plus $12,500 per year for each standing Board committee membership, with 2026 amounts prorated. Subject to their election at the 2026 annual meeting, they will be eligible for an annual restricted stock unit grant targeting $135,000 in value.
The company highlights their deep consumer, digital, turnaround and financial leadership experience to support Weight Watchers’ strategic transformation and growth focus in science-backed weight management and digital health.
WW International (Weight Watchers) announced major leadership and board changes. CEO Tara Comonte resigned effective March 31, 2026, and the company created an Interim Office of the CEO led by CFO Felicia DellaFortuna and COO Jonathan Volkmann while the board conducts a search for a new CEO.
Chief Legal and Administrative Officer and Secretary Jacqueline Cooke will depart April 10, 2026, and will receive a cash separation payment, extended health benefits and legal fee reimbursement under a Separation Agreement. Senior vice president Debra Cotter will become chief legal officer and secretary.
Directors Julie Bornstein and Fallon O’Connor also resigned, and the board reduced its size from seven to four members and amended its bylaws to allow as few as three directors. The company reaffirmed its first quarter 2026 subscriber estimates and full-year 2026 financial guidance.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting 0 shares of common stock of WW International Inc. The filing notes an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report beneficial ownership separately. The filing shows amount beneficially owned: 0 and percent of class: 0%. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
WW International, Inc. Schedule 13G shows that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 591,173 shares of common stock, representing 5.9% of the class as reported on the cover pages.
The filing is a joint filing executed and signed on 03/18/2026 and includes a Joint Filing Agreement among the three filers.
WW International, Inc. reports its annual results and outlines a major post‑bankruptcy reset. The company emerged from Chapter 11 on June 24, 2025, discharging approximately $1,116.0 million of prepetition credit facilities and $500.0 million of senior secured notes. It put in place a new $465.0 million senior secured term loan maturing in 2030 and applied fresh start accounting, creating separate Successor and Predecessor periods.
WW now operates as a single reportable segment built around two main lines: a “Behavioral” subscription business and a U.S. “Clinical” Med+ telehealth offering centered on GLP‑1 and related weight‑management medications. As of the end of fiscal 2025, it had about 2.6 million Behavioral subscribers and 130.2 thousand Clinical subscribers
WW International reported mixed fourth quarter and full-year 2025 results as it transitions from a traditional behavioral weight-loss model to an integrated clinical and GLP-1 focused platform. Q4 2025 total revenue was $163 million, down 12% year-over-year, with behavioral subscription revenue falling 17% while clinical subscription revenue grew 32% to $27 million. The company posted a Q4 net loss of $6 million, a net loss margin of 3.6%, and Adjusted EBITDA of $18 million with an 11.1% margin, down from $46 million and a 25.1% margin a year earlier.
Management highlighted strong momentum in its clinical Med+ offering and GLP-1 Success Program, noting end-of-period clinical subscribers rose 42% to 130,000 within a total subscriber base of 2.8 million. For 2026, WW guided to revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million, and estimated first quarter 2026 end-of-period subscribers of about 2.65 million, including roughly 200,000 clinical subscribers. Following its June 2025 Chapter 11 reorganization, WW ended 2025 with $160 million of cash and a significantly reduced term loan of $465 million, cutting total debt by more than 70% from $1.6 billion and improving net debt to about $305 million.
Cooper Creek Partners Management LLC has disclosed a significant stake in WW International, Inc. As of December 31, 2025, the firm reports beneficial ownership of 649,985 shares of WW International common stock, representing 6.5% of the outstanding class.
Cooper Creek reports sole voting and sole dispositive power over all 649,985 shares, with no shared power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of WW International, indicating a passive investment stance.
WW International director Julie Bornstein reported acquiring 1,166 shares of WW International, Inc. common stock on 01/02/2026. The transaction was coded "A" and priced at $0.00 per share, indicating an award rather than an open‑market purchase. Following this grant, she beneficially owns 2,918 shares of common stock in direct ownership. According to the accompanying note, these shares are subject to transfer restrictions, meaning they cannot be freely sold or transferred until specified conditions are met.
WW International director Michael B. Mason reported acquiring 1,166 shares of common stock on 01/02/2026 at a price of $0.00 per share. After this transaction, he beneficially owned 2,385 shares in total, held directly.
According to the footnote, these shares are subject to transfer restrictions, meaning they cannot be freely sold or transferred until certain conditions are met. The filing reflects a change in Mason's ownership position as a director of WW International, Inc. (ticker WW).
WW International director Eugene I. Davis reported an acquisition of derivative equity awards in the form of deferred stock units. On January 2, 2026, he received 1,166 Deferred Stock Units at a price of $0.00 per unit, increasing his beneficial holdings in these derivatives to 2,385 Deferred Stock Units.
Each Deferred Stock Unit represents the right to receive one share of WW International common stock upon settlement. According to his prior election under the company’s deferred compensation program for non-employee directors, these units will be settled into common shares on the date he separates from service on the company’s board of directors.